Today we can influence overweight and obesity – and thus prevent their consequences, as is the development of diabetes or cardiovascular disease


Published in: Diab Obez 2021; 21(41): 56-58
Category:


Sources
  1. WHO Global Health Observatory Data Repository (online database). World Health Organization: Geneva 2013. Dostupné z WWW: <http://apps.who.int/gho/data/view.main>.
  2. Marketing of foods high in fat, salt and sugar to children: update 2012–2013. WHO Regional Office for Europe: Copenhagen 2013. ISBN 978 92 890 009 3. Dostupné z WWW: <https://www.euro.who.int/__data/assets/pdf_file/0019/191125/e96859.pdf>.
  3. Národný Program Prevencie Obezity (National Obesity Prevention Program). Ministry of Health: Bratislava 2008.
  4. Jensen MD, Ryan DH, Apovian CM et al. [American College of Cardiology/American Heart Association Task Force on Practice Guidelines: Obesity Society]. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines and the Obesity Society. Circulation 2014; 129(25 Suppl 2): S102-S138. Dostupné z DOI: <http://dx.doi.org/10.1161/01.cir.0000437739.71477.ee>.
  5. Heymsfield SB, van Mierlo CA, van der Knaap HC et al. Weight management using a meal replacement strategy: meta- and pooling-analyssi from six studies. Int J Obes Relat Metab Disord 2003; 27(5): 537–549. Dostupné z DOI: <http://dx.doi.org/10.1038/sj.ijo.0802258>.
  6. Wadden TA, Walsh OA, Berkowitz RI et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial. Obesity (Silver Spring) 2019; 27(1): 75–86. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22359>.
  7. Wadden TA, Tronieri JS. Sugimoto D et al. Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE INT randomized controlled trial. Obesity (Silver Spring) 2020; 28: 529–536. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22726>.
  8. Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use (prescribing information). Informace dostupné z WWW: <http://www.fda.gov>.
  9. Ahrén B, Masmiquel L, Kumar H et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidine-diones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol 2017; 5(5): 341–354. Dostupné z DOI: <http://dx.doi.org/10.1016/S2213–8587(17)30092-X>.
  10. Ahmann AJ, Capehorn M, Charpentier G et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care 2018; 41(2): 258–266. Dostupné z DOI: <http://dx.doi.org/10.2337/dc17–0417>.
  11. O’Neil PM, Birkenfeld AL, McGowan B et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018; 392(10148): 637–649. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)31773–2>.
  12. Kushner RF, Calanna S, Davies M et al. Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity (Silver Spring) 2020; 28: 1050–1061. Dostupné z DOI: <http://dx.doi.org/10.1002/oby.22794>.
  13. Webb VL, Wadden TA. Intensive lifestyle intervention for obesity: principles, practices, and results. Gastroenterology 2017; 152(7): 1751–1764. Dostupné z DOI: <http://dx.doi.org/10.1053/j.gastro.2017.01.045>.
  14. Gabery S, Salinas CG, Paulsen SJ et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight 2020; 5(6): e133429. Dostupné z DOI: <http://dx.doi.org/10.1172/jci.insight.133429>.
  15. Friedrichsen M, Breitschaft A, Tadayon S et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23(3): 754–262. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.14280>.
  16. Wing RR, Lang W, Wadden TA et al. Look AHEAD Research Group. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011; 34(7): 1481–1486. Dostupné z DOI: <http://dx.doi.org/10.2337/dc10–2415>.
  17. Ryan DH, Yockey SR. Weight loss and improvements in comorbidity: differences at 5%, 10%, 15%, and over. Curr Obes Rep 2017; 6(2): 187–194. Dostupné z DOI: <http://dx.doi.org/10.1007/s13679–017–0262-y>.
  18. Gregg EW, Chen H, Wagenknecht LE et al. [Look AHEAD Research Group]. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA 2012; 308(23): 2489–2496. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2012.67929>.
  19. Kuna ST, Reboussin DM, Strotmeyer ES et al. Sleep AHEAD Research Subgroup of the Look AHEAD Research Group. Effects of weight loss on obstructive sleep apnea severity: ten-year results of the Sleep AHEAD study. Am J Respir Crit Care Med 2021; 203(2): 221–229. Dostupné z DOI: <http://dx.doi.org/10.1164/rccm.201912–2511OC>.
  20. Bettge K, Kahle M, Abd El Aziz MJ et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials. Diabetes Obes Metab. 2017; 19(3): 336–347. Dostupné z DOI: <http://dx.doi.org/10.1111/dom.12824>.
Labels
Diabetology Obesitology

Article was published in

Diabetes a obezita

Issue 41

2021 Issue 41

Most read in this issue
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account